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Background: Skin cancer accounts for one third of all cancers. Prognosis is inversely related to identiﬁ-
cation stage.
Objectives: To describe a novel service, mole scans, performed in community pharmacy, the ﬁndings
from the ﬁrst 3.5 years it was in place, and to explore patient acceptability of the service.
Methods: Norwegian Boots' pharmacies offer a mole scanning service in cooperation with ScreenCancer.
Scans are undertaken within pharmacy consultation rooms. Image interpretation is undertaken remotely
by a specialist. Number and result of scans performed from 2010 to 2014 are reported. A satisfaction
questionnaire was returned by 10% of participants.
Results: A total of 25836 scans were performed on 15777 individuals. Of these, 83.6% had normal scans,
1% had melanoma, and 15.4% had another skin condition. In 2014 the service identiﬁed 4.1% of melanoma
cases registered in the Norwegian Cancer Registry. Most responders (88%) would use a similar service
again. Nearly all (99%) felt the pharmacy was a suitable venue, and 95% would recommend the service to
others. In total, 99% of respondents scored their overall satisfaction as “good” or higher.
Conclusions: This approach was acceptable among participants who provided feedback. Providing mole
scanning through pharmacies enables individuals to obtain a rapid check of moles causing concern, in an
acceptable environment with a high level of satisfaction.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Skin cancer accounts for one third of all cancers being diagnosed
globally and its incidence is increasing.1 Prognosis for the disease is
inversely related to the stage of identiﬁcation2,3 and consequently
effective approaches for identifying suspect lesions at an early stage
are required.4 Whilst evidence supporting the cost-effectiveness of
population screening for malignant melanoma is weak it has been
suggested that focussing on high-risk individuals is likely to be
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acy (2016), http://dx.doi.orgThe main strategy currently used to identify skin cancer at an
early stage is raising public awareness of melanoma, and self-
referral to a general practitioner (GP) when moles change in
appearance.7 This approach requires GPs to be suitably trained to
identify the moles that require referral to a dermatologist,8 and the
public having sufﬁcient access to such services.
One approach to improve early identiﬁcation is to provide a
mole scanning service through pharmacies. Due to extended
opening hours, the presence of healthcare professionals, ease of
access, and availability of consultation rooms, community phar-
macies are increasingly being used for the provision of early
detection services as part of their public health remit.9
In 2010 ScreenCancer, who provides cancer screening services,
set up a novel mole scanning services in cooperation with Boots
Norge AS, in Boots community pharmacies. Scans were undertaken
within consultation rooms in the pharmacy, while thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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specialist in dermatology. Whilst participant feedback on the ser-
vice was sought during the ﬁrst years, the acceptability and effec-
tiveness of this service have not been reported.
2. Objectives
The objectives of this service evaluationwere to describe a novel
community pharmacy service, and to report ﬁndings from the ﬁrst
3½ years when the service was in place. The paper will also explore
patient acceptability of mole scans performed in community
pharmacies.
3. Methods
3.1. Setting & study duration
The service was provided from Boots community pharmacies in
Norway. In this paper, data are presented from all who purchased
the service from when it was introduced in August 2010,
throughout 2014.
3.2. Intervention
Moles were scanned using the ScreenCancer Mole Navigator®
system, in combination with SIAscope-technology. SIAscopy is a
non-invasive scanning technique where a handheld device shines
near infrared and visible spectra light though the skin. The image
shows collagen and haemoglobin content of the papillary dermis,
andmelanin content of the epidermis and papillary dermis that can
indicate pathological changes consistent with melanoma.10 The
image captured in the pharmacy was sent to a trained specialist in
dermatology for interpretation. The method shows a reported
sensitivity in a similar setting of 94.5% and a speciﬁcity of 64%.11
Fig. 1 shows the basic steps of the service.
The patient received a letter from ScreenCancer with the result
of the scanwithin 2 weeks. If the mole was deemed to need further
investigation, health personnel in ScreenCancer contacted the in-
dividual by phone and provided advice on how to proceed. The
customer was then contacted again after approximately 2 months,
and the result of the follow up was recorded in ScreenCancer's ﬁles.Fig. 1. Overview over the ScreenCancer mole scan
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Pharmacies raised awareness of the service and the importance
of sun protection and self-checks of moles by providing an infor-
mation leaﬂet to pharmacy patients about skin cancer which
described the ABCDE-criteria12 used to identify suspicious moles.
3.4. Staff training
All pharmacy staff performing mole scans were required to read
the procedure involved and take an online course, followed by
practical training in use of the Siascope and the Mole Navigator®
system. A ﬁnal practical test, where the employee performed the
service and the resulting scans were approved by ScreenCancer,
was required before certiﬁcation was given.
3.5. Inclusion criteria
Patients self-selected for the service and identiﬁed the moles
they wanted to scan, paying a set fee per mole, 350 NOK (approx-
imately 50 USD) for the ﬁrst mole, and 150 NOK (21 USD) for
subsequent scans.
If they were unsure as to which moles to scan, or if there were
more than 3 suspicious moles, the pharmacy staff referred the in-
dividual to their GP.
3.6. Data collection
Anonymous information, including number and result of scans,
was extracted from the computer system for all patients accessing
the service. Gender was not included in the database; therefore, the
investigators used ScreenCancer's ﬁles to obtain this data for
random sample of participants to provide some insight into the
population accessing the service. Numbers on the national identi-
ﬁcation rates are publicly available, and were obtained through the
website of the Cancer Registry of Norway.13
During the ﬁrst 2 years and 8 months after implementing the
service (August 2010eMay 2013), alongside the scan results that
were sent to patients, Screencancer included a simple, non-
validated patient satisfaction questionnaire and a pre-paid return
envelope. The questionnaire consisted of questions regardingning service in Boots pharmacies in Norway.
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Sun damage 45 2.5
Other skin condition 413 23.0
Melanoma: cancer or pre-cancer 154 8.6
Other skin cancer 166 9.3
Customer did not follow-up/could
not conﬁrm result with customer
100 5.6
Total 1793 100
R.L.S. Kjome et al. / Research in Social and Administrative Pharmacy xxx (2016) 1e4 3suitability of location, staff competence, quality of information
provided, total satisfaction and whether they would use the service
again or recommend it to others. Reminders were not sent out if
patients did not respond as responses were anonymous.
3.7. Data analysis
Data analysis was purely descriptive, using measures of central
tendency, description of variance and proportion, as appropriate.
The Cancer Registry of Norway was used to identify the
contribution the service had made to national detection rates.
3.8. Ethical approval
No ethics approval was needed as this was a routine service
evaluation where data which was analysed was anonymous and
had been routinely collected.
4. Results
4.1. Demographics
During the period from 2010 throughout 2014 a total of 25836
scans were performed on 15777 individuals in 109 differentFig. 2. The reported satisfaction of respondents aft
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median age was 56 (mean 52.7). Among the 410 persons for whom
gender was recorded 290 (71%) were female.
4.2. Scan results
Of the 25836 scans, 22803 (88.3%) were normal, 631 (2.4%)
showed non-cancerous sun damage, and 369 (1.4%) showed other,
non-cancerous skin condition. The remaining 2033 images (7.9%)
(1813 individuals) required further conﬁrmatory tests. Table 1
provides the results in the 1793 individuals that ScreenCancer
were able to follow up. In total, 13185 individuals (83.6%) had only
normal scans, 154 (1%) were found to have melanoma, and 2438
(15.4%) had some other skin condition.
4.3. Contribution to national identiﬁcation rates
In 2011, the Cancer Registry of Norway13 stated 1747 cases of
melanoma; in 2012, 1779 cases; in 2013, 1738 cases; and in 2014,
2003cases.Of these, theBootsmole scanning service found15 (0.9%)
in 2011, 18 (1%) in 2012, 38 (2.2%) in 2013 and 83 (4.1%) in 2014.
4.4. Patient satisfaction
A total of 690 persons returned the satisfaction questionnaire
out of 6930 individuals that were scanned in the period from 2010
throughout April 2013, thus yielding a response rate of 10%. The
majority (88%) answered that theywould use similar services in the
future, 11% said maybe and 1% said no. Most participants (99%) felt
that the pharmacy was a suitable venue for such a service, and 95%
would recommend the service to others. Fig. 2 shows how the re-
sponders scored their satisfaction.
5. Discussion
In this paper, data collected as part of an ongoing service in
Boots community pharmacies was used to assess outcomes ander using the pharmacy mole scanning service.
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pharmacy. To the authors' knowledge, this is the ﬁrst paper
reporting the results of mole scans performed in community
pharmacies.
A large majority of the responding patients believed that com-
munity pharmacy was a suitable location for mole scans, stating
that they would use the service again and recommend it to others.
On the whole, satisfaction was high; nearly all respondents scored
their total satisfaction as good, very good or extremely good. At the
end of data collection in 2013, ScreenCancer and Boots Norway AS
used the patient feedback to improve the staff training program by
adding an e-learning course with instructive videos, to further
improve staff competency and the information given to patients.
By uncovering melanoma in 1% of those who attended the ser-
vice, which in 2014 accounted for 4% of the total cases identiﬁed
nationally, and by uncovering other, less serious skin conditions,
the service shows potential to beneﬁt public health. The informa-
tion the pharmacies provided on advocating staying safe in the sun
and use of sun protection products also had a potential public
health beneﬁt.
The substantial number of pharmacy patients who chose to use
the pharmacy and pay themselves rather than going to their GP for
the initial scan represents a potential signiﬁcant saving for the
government and the importance placed on this service by patients.
Furthermore, using pharmacies as the ﬁrst-line identiﬁer to sepa-
rate those who require follow up from those who do not, gives the
GPs and the specialists more time for those who require inter-
vention. It is not possible to identify what proportion of individuals
seenwithin the pharmacywhowould have gone to their doctor had
the service not existed and therefore one cannot determine the true
cost saving. If, however, the service recruited mainly individuals
who would otherwise not have been tested, this would mean
reaching a broader segment of the population, thus allowing for
early treatment of cases that otherwise would not have been found
at an early stage.
5.1. Limitations
This paper reports the results of the implementation of a novel
community pharmacy service. The service has not been assessed
for cost-effectiveness.
While the responders to the satisfaction questionnaire were
very positive towards the service, the questionnaire used was a
simple, non-validated questionnaire, developed by the service
providers, and thus the results must be interpreted with caution.
Further, the low response rate means limits generalizability of
responses.
6. Conclusion
While further studies are required to assess cost-effectiveness,
results from 3.5 years of mole scanning in a community phar-
macy setting suggests that the service contributes to earlier iden-
tiﬁcation of skin cancer at no additional cost to the government and
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